Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties ...
The company also agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights. Also Read: Ventyx Biosciences’ Inflammatory Bowel Disease ...
Some results have been hidden because they may be inaccessible to you